MK-677 (ibutamoren) is not a SARM. It is a growth hormone secretagogue, a completely different class of compound that works through a different receptor and produces different effects in the body. The two get lumped together because they’re often sold side by side on the same supplement websites, but pharmacologically they have almost nothing in common.
Why MK-677 Gets Mislabeled as a SARM
SARMs (selective androgen receptor modulators) bind to androgen receptors, the same receptors that testosterone activates. They were developed to provide some of the muscle-building effects of anabolic steroids with fewer side effects in other tissues. MK-677 doesn’t interact with androgen receptors at all. It mimics a hormone called ghrelin and binds to ghrelin receptors in the brain, triggering the pituitary gland to release more growth hormone.
The confusion exists almost entirely because of marketing. Online retailers sell MK-677 alongside actual SARMs like ostarine and ligandrol, often under a shared “SARMs” category. Fitness forums repeat the label. Over time, the association sticks, even though calling MK-677 a SARM is like calling ibuprofen an antibiotic because they’re sold in the same aisle.
How MK-677 Actually Works
MK-677 is an orally active, nonpeptide mimic of growth hormone-releasing peptide. When you take it, it stimulates endogenous growth hormone release, meaning your own pituitary gland produces more GH rather than you injecting synthetic growth hormone from outside. A single dose in one study produced a peak growth hormone response of about 56 micrograms per liter, compared to roughly 9 micrograms per liter with a placebo. After a week of daily dosing, the peak settled to about 23 micrograms per liter, still roughly triple the placebo level.
The downstream effect that matters most is a rise in IGF-1, a hormone closely tied to tissue growth and repair. In a year-long trial, a daily 25 mg dose increased IGF-1 levels by about 60% at six weeks and nearly 73% at twelve months. That sustained elevation is what makes MK-677 appealing to people looking for body composition changes: studies on growth hormone secretagogues show comparable fat loss and lean mass gains to those seen with injectable recombinant growth hormone therapy.
How SARMs Differ
SARMs work through the androgen-dependent gonadal axis, the same hormonal pathway as testosterone. Testosterone therapy remains the gold standard for conditions like hypogonadism because it can reduce visceral fat, increase lean body mass, improve bone health, and enhance sexual function. SARMs attempt to deliver a subset of those effects more selectively.
Growth hormone secretagogues like MK-677 operate on an entirely independent axis. They address body composition through the growth hormone and IGF-1 pathway rather than through androgens. This means MK-677 does not suppress your natural testosterone production, which is one of the primary concerns with actual SARMs. It also means the side effect profiles are completely different.
Side Effects of MK-677
Because MK-677 activates the ghrelin receptor, increased appetite is one of the most consistent effects. For some users this is a benefit; for others trying to stay in a calorie deficit, it’s a significant drawback. Fluid retention (edema) and muscle pain are also commonly reported.
The more concerning effect involves blood sugar. In a study of older adults taking 25 mg daily, fasting glucose rose from 5.4 to 6.8 mmol/L within four weeks, a statistically significant jump that pushes into prediabetic territory. Growth hormone naturally antagonizes insulin, so chronically elevated GH levels can reduce insulin sensitivity over time. The FDA has specifically flagged potential alterations in glucose metabolism and insulin sensitivity as risks, along with a note that MK-677 may increase the potential for congestive heart failure in certain individuals.
Long-term effects remain largely unknown. Published trials have lasted up to about a year, but most ran for weeks to months.
Regulatory and Legal Status
MK-677 has not been approved by the FDA for any medical use. Its safety and efficacy have not been formally established. The FDA has issued warnings when it has been found as a hidden ingredient in consumer supplements, including a children’s growth formula that contained undeclared ibutamoren.
In competitive sports, MK-677 is prohibited. The World Anti-Doping Agency classifies it under “Growth Hormone Releasing Factors,” which falls within the broader category of peptide hormones, growth factors, and related substances. It is not listed under any SARM category on the prohibited list, further confirming its distinct classification. It is banned at all times, both in and out of competition.
The Bottom Line on Classification
MK-677 is a growth hormone secretagogue that acts on ghrelin receptors to boost your body’s own growth hormone and IGF-1 production. SARMs act on androgen receptors to mimic testosterone-like effects in muscle and bone. The two compounds target different receptors, work through different hormonal pathways, carry different side effect profiles, and are regulated under different categories. The only thing they genuinely share is shelf space on supplement websites.